Table 3.
Pathology results for the active and placebo group for all participants.
| Active | Placebo | |||||
|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Baseline | Month 3 | Month 6 | |
| ALT (U/L) | 25.9 ± 15.6 | 20.9 ± 7.9 | 23.3 ± 9.1 | 25.9 ± 11.5 | 23.6 ± 10.6 | 24.7 ± 10.0 |
| AST (U/L) | 23.7 ± 7.2 | 23.4 ± 8.2 | 25.8 ± 9.1 | 22.2 ± 9.8 | 22.3 ± 8.9 | 23.1 ± 10.4 |
| GGT (U/L) | 29.7 ± 15.3 | 26.3 ± 14.7 | 24.3 ± 13.9 | 36.4 ± 25.7 | 33.1 ± 28.2 | 32.7 ± 28.3 |
| TBIL (umol/L) | 11.9 ± 4.5 | 11.9 ± 4.7 | 12.3 ± 5.6 | 11.7 ± 5.0 | 11.1 ± 4.8 | 11.0 ± 3.9 |
| Cholesterol (umol/L) | 5.8 ± 1.1 | 5.7 ± 1.1 | 5.7 ± 1.2 | 5.8 ± 1.2 | 5.6 ± 1.1 | 5.7 ± 1.1 |
| HDL (mmol/L) | 1.8 ± 0.4 | 1.8 ± 0.5 | 1.9 ± 0.6 | 1.7 ± 0.5 | 1.6 ± 0.5 | 1.7 ± 0.4 |
| LDL (pg/mL) | 3.6 ± 0.9 | 3.5 ± 0.9 | 3.5 ± 0.9 | 3.7 ± 1.0 | 3.5 ± 1.0 | 3.5 ± 0.8 |
| TRI (mmol/L) | 1.0 ± 0.4 | 1.0 ± 0.5 | 1.1 ± 0.7 | 1.4 ± 0.7 | 1.3 ± 0.7 | 1.3 ± 0.7 |
| Glucose (mmol/L) | 5.6 ± 1.0 | 5.6 ± 0.8 | 5.5 ± 0.9 | 5.6 ± 1.0 | 5.6 ± 0.8 | 5.7 ± 0.8 |
| Insulin (mU/L) | 12.2 ± 8.1 | 13.0 ± 9.9 | 11.4 ± 7.9 | 11.2 ± 6.6 | 12.0 ± 7.8 | 12.7 ± 8.4 |
| Creatine (umol/L) | 92.4 ± 11.8 | 96.4 ± 21.8 | 94.0 ± 13.3 | 90.9 ± 18.1 | 94.2 ± 15.4 | 93.2 ± 14.6 |
| Ghrelin (ng/mL) | 0.41 ± 0.32 | 0.47 ± 0.51 | 0.49 ± 0.47 | 0.40 ± 0.36 | 0.39 ± 0.34 | 0.40 ± 0.38 |
| Leptin (ng/mL) | 5.71 ± 5.13 | 5.10 ± 5.72 | 5.51 ±7.11 | 4.77 ±4.10 | 4.06 ± 3.50 | 3.9 ±3.64 |
| Adiponectin (ug/mL) | 6.26 ± 3.77 | 6.43 ± 4.11 | 6.35 ± 3.62 | 5.22 ± 3.59 | 5.21 ± 3.50 | 5.54 ± 3.83 |
ALT = Alanine transaminase, AST = Aspartate aminotransferase, GGT = Gamma-glutamyl transferase, TBIL = total bilirubin, GLU = glucose, TRI = triglycerides, HDL = high density lipoproteins, LDL = low density lipoproteins. Values represented as mean ± SD.